Lantheus adds TAUKLARIFY to Alzheimer’s imaging toolkit after FDA approval
FDA approves TAUKLARIFY for tau PET imaging in Alzheimer’s evaluation. See how Lantheus’ new tracer fits into the evolving diagnostic market.
Medical Devices & Diagnostics
Pharma & Biotech
Alzamend Neuro moves AL001 into bipolar disorder patients as lithium reformulation race intensifies
Alzamend Neuro, the Nasdaq-listed clinical-stage biopharmaceutical company, has initiated a Phase II clinical trial of AL001, its ionic cocrystal lithium formulation, in patients diagnosed with bipolar disorder type 1, conducting the study at Massachusetts General Hospital in collaboration with Harvard Medical School investigators. The trial employs a crossover design in which participants receive both AL001